ArticleMolecular psychiatry2022
Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability.
Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Modifiable Nutritional Biomarkers in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis of Vitamin D, BInternational journal of molecular sciences · 2025Pooled it
- Immune and Autoimmune Mechanisms in Autism Spectrum Disorder: Linking Molecular Pathways to Neuropsychological Trajectories Across the Lifespan.International journal of molecular sciences · 2026Review
- A Survey-Based Study Investigating Opinions on Genetic Research Among Swedish Autistic Individuals and Parents of Autistic Children.Autism : the international journal of research and practice · 2026Article
- Enigma of autism regression mechanistic pathways, clinical phenotypes, and early intervention implications.World journal of clinical pediatrics · 2026Review
- Analytical Validation of an ELISA Assay for Maternal Autoantibody-Related Autism.Diagnostics (Basel, Switzerland) · 2026Article
- Utilizing maternal autoantibody patterns to predict risk of autism and intellectual disability in offspring.Research square · 2026Article
- From Genetic Determinism to Epigenetic Regulation: Paradigm Shifts in the Understanding of Neurodevelopmental Disorders.Current issues in molecular biology · 2026Review
- Effects of maternal autoantibody exposure at the cellular level: implications for the developing brain.Frontiers in psychiatry · 2026Review
- Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.Human reproduction open · 2026Article
- An overview of oxytocin integrative mechanisms in autism spectrum disorder.Discover mental health · 2025Review
- Heterogeneity of anti-Caspr2 antibodies: specificity and pathogenicity.Translational psychiatry · 2025Article
- Autism Spectrum Disorder: What Do We Know and Where Do We Go?Brain sciences · 2025Review
- Gestational autoantibody exposure impacts early brain development in a rat model of MAR autism.Molecular psychiatry · 2025Article
- Review
- Inhibiting proBDNF to mature BDNF conversion leads to ASD-like phenotypes in vivo.Molecular psychiatry · 2024Article
- Engineering antigen-presenting cells for immunotherapy of autoimmunity.Advanced drug delivery reviews · 2024Review
- Differences in mid-gestational and early postnatal neonatal cytokines and chemokines are associated with patterns of maternal autoantibodies in the context of autism.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Prenatal and postnatal neuroimmune interactions in neurodevelopmental disorders.Nature immunology · 2024Review
- Altered cytokine and chemokine profile linked to autoantibody and pathogen reactivity in mothers of autistic children.Frontiers in psychiatry · 2024Article
- Identification and prediction model of placenta-brain axis genes associated with neurodevelopmental delay in moderate and late preterm children.BMC medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Maternal autoantibody-related ASD (MAR ASD) is a subtype of autism in which pathogenic maternal autoantibodies (IgG) cross the placenta, access the developing brain, and cause neurodevelopmental alterations and behaviors associated with autism in the exposed offspring. We previously reported maternal IgG response to eight proteins (CRMP1, CRMP2, GDA LDHA, LDHB, NSE, STIP1, and YBOX) and that reactivity to nine specific combinations of these proteins (MAR ASD patterns) was predictive of ASD risk. The aim of the current study was to validate the previously identified MAR ASD patterns (CRMP1 + GDA, CRMP1 + CRMP2, NSE + STIP1, CRMP2 + STIP1, LDHA + YBOX, LDHB + YBOX, GDA + YBOX, STIP1 + YBOX, and CRMP1 + STIP1) and their accuracy in predicting ASD risk in a prospective cohort employing maternal samples collected prior to parturition. We used prenatal plasma from mothers of autistic children with or without co-occurring intellectual disability (ASD = 540), intellectual disability without autism (ID = 184) and general population controls (GP = 420) collected by the Early Markers for Autism (EMA) study. We found reactivity to one or more of the nine previously identified MAR ASD patterns in 10% of the ASD group compared with 4% of the ID group and 1% of the GP controls (ASD vs GP: Odds Ratio (OR) = 7.81, 95% Confidence Interval (CI) 3.32 to 22.43; ASD vs ID: OR = 2.77, 95% CI (1.19-7.47)) demonstrating that the MAR ASD patterns are strongly associated with the ASD group and could be used to assess ASD risk prior to symptom onset. The pattern most strongly associated with ASD was CRMP1 + CRMP2 and increased the odds for an ASD diagnosis 16-fold (3.32 to >999.99). In addition, we found that several of these specific MAR ASD patterns were strongly associated with ASD with intellectual disability (ASD + ID) and others associated with ASD without ID (ASD-no ID). Prenatal screening for these MAR patterns may lead to earlier identification of ASD and facilitate access to the appropriate early intervention services based on each child's needs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.